Good Growth Opportunities in Global Cancer Biological Therapy Market FMI Releases New Report on the Cancer Biological T | Page 6

Report
Description
Report Description
Cancer Biological Therapy Market: Overview
The immune system protects a person from infection and disease. The Biological
therapies are used to lessen the spread and lower the risk of recurrence for some
cancers, slow the growth, control symptoms of cancer, deliver radioactive substances or
chemotherapy drugs directly to a tumour lessen and some of the side effects from cancer
treatments. Immune system recognize antigens on the surface of viruses, bacteria, other
germs and cancer cells. Antigens mark these cells as being different (foreign) so the
immune system can find them. The immune system reacts to these antigens and destroys
the cells they are attached to. According to Globocan, in economically developed
countries, 58% of all newly diagnosed cancer cases occur at 65 years of age and older,
compared with 40% in developing countries. When countries are grouped according to
income, cancer is the second leading cause of death in high-income countries and the
third leading cause of death in low- and middle-income countries. Among females, the
most common cancer sites were either breast or cervical cancer, with the exceptions of
South Korea (thyroid), Mongolia and Laos (liver) and China and North Korea (lung).
Cancer Biological Therapy Market: Regional Overview
Geographically, the market is dominated by North America, followed by Europe, Asia
Pacific. Growth in the North American segment is primarily driven by presence of large
number of cancer biological drug and vaccine manufacturers, increasing disposable
income, affordable cancer treatment facility and growing number of health insurance
coverage for life-threatening diseases. According to National Cancer Institute (NCI) an